Literature DB >> 1850968

Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases.

K Hoshino1, K Sato, K Akahane, A Yoshida, I Hayakawa, M Sato, T Une, Y Osada.   

Abstract

A study was made of the correlation between the in vitro inhibitory effects of several quinolones, including four ofloxacin derivatives, on bacterial DNA gyrase from Escherichia coli KL-16 and on topoisomerase II from fetal calf thymus. No correlation was observed between the inhibitions of DNA gyrase activity and topoisomerase II activity. On the other hand, the inhibitory effects of these quinolones against topoisomerase II were closely correlated with their inhibition of cell growth. Furthermore, among the oxazine derivatives tested, the derivative with a methyl group at position 3 in an S configuration showed the highest activity against DNA gyrase and derivatives without a methyl group on the oxazine ring were more potent against topoisomerase II than those with a methyl group. Among these derivatives, DR-3355, the S isomer of ofloxacin, showed the highest activity against DNA gyrase and low activity against topoisomerase II. These results indicate that the methyl group on the oxazine ring plays an important role in the inhibitory activities of ofloxacin derivatives for these enzymes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1850968      PMCID: PMC244997          DOI: 10.1128/AAC.35.2.309

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model.

Authors:  L L Shen; L A Mitscher; P N Sharma; T J O'Donnell; D W Chu; C S Cooper; T Rosen; A G Pernet
Journal:  Biochemistry       Date:  1989-05-02       Impact factor: 3.162

2.  Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus.

Authors:  K Hoshino; K Sato; T Une; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

3.  Effects of fleroxacin on HeLa cell functions and topoisomerase II.

Authors:  Y Oomori; T Yasue; H Aoyama; K Hirai; S Suzue; T Yokota
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

4.  Physical separation of hemopoietic stem cells from cells forming colonies in culture.

Authors:  R G Worton; E A McCulloch; J E Till
Journal:  J Cell Physiol       Date:  1969-10       Impact factor: 6.384

5.  In vitro activity of DR-3355, an optically active ofloxacin.

Authors:  T Une; T Fujimoto; K Sato; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA.

Authors:  L L Shen; A G Pernet
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

7.  Purification and characterization of a type II DNA topoisomerase from bovine calf thymus.

Authors:  B D Halligan; K A Edwards; L F Liu
Journal:  J Biol Chem       Date:  1985-02-25       Impact factor: 5.157

8.  Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts.

Authors:  P Hussy; G Maass; B Tümmler; F Grosse; U Schomburg
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

9.  Synthesis and bacterial DNA gyrase inhibitory properties of a spirocyclopropylquinolone derivative.

Authors:  M P Wentland; R B Perni; P H Dorff; J B Rake
Journal:  J Med Chem       Date:  1988-09       Impact factor: 7.446

10.  Synthesis, absolute configuration, and antibacterial activity of 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H- benzo[ij]quinolizine-2-carboxylic acid.

Authors:  J F Gerster; S R Rohlfing; S E Pecore; R M Winandy; R M Stern; J E Landmesser; R A Olsen; W B Gleason
Journal:  J Med Chem       Date:  1987-05       Impact factor: 7.446

View more
  14 in total

1.  Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.

Authors:  T Akasaka; S Kurosaka; Y Uchida; M Tanaka; K Sato; I Hayakawa
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

2.  Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition.

Authors:  K Hoshino; A Kitamura; I Morrissey; K Sato; J Kato; H Ikeda
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

3.  A pyrimido[1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential.

Authors:  A H Corbett; P Guerry; P Pflieger; N Osheroff
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

Review 4.  Quinolone mode of action--new aspects.

Authors:  D C Hooper
Journal:  Drugs       Date:  1993       Impact factor: 9.546

5.  Mechanism of differential activities of ofloxacin enantiomers.

Authors:  I Morrissey; K Hoshino; K Sato; A Yoshida; I Hayakawa; M G Bures; L L Shen
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

6.  Contribution of topoisomerase IV mutation to quinolone resistance in Mycoplasma genitalium.

Authors:  Yuko Yamaguchi; Masaya Takei; Ryuta Kishii; Mitsuru Yasuda; Takashi Deguchi
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

7.  Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group.

Authors:  M J Robinson; B A Martin; T D Gootz; P R McGuirk; N Osheroff
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

8.  Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential.

Authors:  S H Elsea; P R McGuirk; T D Gootz; M Moynihan; N Osheroff
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

9.  Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme.

Authors:  S J Froelich-Ammon; P R McGuirk; T D Gootz; M R Jefson; N Osheroff
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  CP-115,953 stimulates cytokine production by lymphocytes.

Authors:  K Riesbeck; A Forsgren
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.